TMDX
NASDAQTransMedics Group Inc.
Website
News25/Ratings12
News · 26 weeks39-43%
2025-10-262026-04-19
Mix2490d
- Insider9(38%)
- SEC Filings6(25%)
- Other6(25%)
- Earnings3(13%)
Latest news
25 items- PRTransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual MeetingUnveils New Controlled Hypothermic Organ Preservation System (CHOPS) to Expand its Product Portfolio and to Facilitate Enrollment in Control Arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung Clinical TrialsANDOVER, Mass., April 23, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, is today providing an update on its ongoing clinical programs at the International Society of Heart and Lung Transplantation (ISHLT) 2026 Annual Meeting in Toronto, Canada. At the meeting, TransMedics will unveil its new controlled, active cooling preser
- PRTransMedics to Report First Quarter 2026 Financial Results on May 5, 2026ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic c
- SECSEC Form DEFA14A filed by TransMedics Group Inc.DEFA14A - TransMedics Group, Inc. (0001756262) (Filer)
- SECSEC Form DEF 14A filed by TransMedics Group Inc.DEF 14A - TransMedics Group, Inc. (0001756262) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TransMedics Group Inc.SCHEDULE 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
- INSIDERSEC Form 3 filed by new insider Forsyth Matthew S.3 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Lovell Stephanie sold $178,497 worth of shares (1,193 units at $149.62), decreasing direct ownership by 29% to 2,866 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Weill David exercised 3,571 shares at a strike of $14.20 and sold $524,294 worth of shares (3,571 units at $146.82) (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERChief Financial Officer Hernandez Gerardo sold $1,117,382 worth of shares (7,611 units at $146.81) and exercised 7,236 shares at a strike of $71.17, decreasing direct ownership by 2% to 14,689 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDEROfficer Ranganath Anil P. sold $120,200 worth of shares (864 units at $139.12), decreasing direct ownership by 6% to 13,091 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDEROfficer Corcoran Nicholas covered exercise/tax liability with 984 shares and sold $412,630 worth of shares (2,966 units at $139.12), decreasing direct ownership by 12% to 29,831 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- SECSEC Form 8-K filed by TransMedics Group Inc.8-K - TransMedics Group, Inc. (0001756262) (Filer)
- PRTransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial ResultsANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended December 31, 2025. As previously disclosed, in the fourth quarter of 2025, TransMedics released a $103.3 million U.S. tax valuation allowance, which drove recognition of a
- SECSEC Form 10-K filed by TransMedics Group Inc.10-K - TransMedics Group, Inc. (0001756262) (Filer)
- SECTransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TransMedics Group, Inc. (0001756262) (Filer)
- PRTransMedics Reports Fourth Quarter and Full Year 2025 Financial ResultsANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025. Recent Highlights Total revenue of $160.8 million in the fourth quarter of 2025, a 32% increase compared to the fourth quarter of 2024Total revenue of $605.5 million in the full year 2025, a 37% increase compared to the full year 2024Generated net income of $105.4 m
- INSIDERChief Commercial Officer Cecere Giovanni was granted 11,082 shares, increasing direct ownership by 139% to 19,057 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERAmendment: New insider Cecere Giovanni claimed ownership of 7,975 shares (SEC Form 3)3/A - TransMedics Group, Inc. (0001756262) (Issuer)
- PRTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)ANDOVER, Mass., Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 18, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 40,089 shares of its common stock and an aggregate of 26,549 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants included stock options to purchase 16,734 shares of TransMedics' common stock and 11,082 restricted stock units granted to Giovanni Cecere, the
- PRTransMedics to Present at Upcoming March Investor ConferencesANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on Monday, March 2, 2026, at 1:50 p.m. EST and virtually at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Monday, March 16, 2026, at 10:00 a.m. EST.
- INSIDERSEC Form 3 filed by new insider Cecere Giovanni3 - TransMedics Group, Inc. (0001756262) (Issuer)
- PRTransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (800) 7
- PRTransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE TrialANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial. This follows full FDA approval of the company's Next-Generation OCS DENOVO Lung IDE trial in January 2026 and conditional IDE approval for the ENHANCE Heart trial in August 2025.
- SECSEC Form 8-K filed by TransMedics Group Inc.8-K - TransMedics Group, Inc. (0001756262) (Filer)
- PRTransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, MassachusettsANDOVER, Mass., Jan. 12, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a global leader in organ transplant technologies and services, today announced the signing of a long-term lease for its new global headquarters at Assembly Innovation Park in Somerville, as well as the acquisition of the adjacent land parcel to create an integrated TransMedics campus environment. This strategic expansion reflects the company's commitment to accelerating the next wave of transplant innovations, growth, and the transformation of global organ transplant therapy.